Aromatase inhibitors: Structural features and biochemical characterization

Annals of the New York Academy of Sciences

Volumn 1089, Issue , 2006, Pages 237-251

  Hong, Yanyan ^a   Chen, Shiuan ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Flavonoid phytoestrogen; Mechanism based inhibitor; Structural model

Indexed keywords

10 PROPARGYLESTR 4 ENE 3,17 DIONE; 3 (IMIDAZOLYLMETHYL) 4' NITROFLAVONE; 4 BENZYL 3 (4' CHLOROPHENYL) 7 METHOXYCOUMARIN; 6 ALPHA BROMOANDROSTENEDIONE; 7 HYDROXY 3 (4 METHOXYPHENYL) 2 [(4' PYRIDYLMETHYL)THIO]ISOFLAVONE; 7 HYDROXYFLAVANONE; 7 HYDROXYFLAVONE; ALPHA NAPHTHOFLAVONE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROST 4 ENE 3,6,17 TRIONE; ANDROSTA 1,4,6 TRIENE 3,17 DIONE; APIGENIN; AROMATASE; AROMATASE INHIBITOR; BAICALEIN; CHRYSIN; COUMARIN DERIVATIVE; EQUOL; EXEMESTANE; FADROZOLE; FLAVONE DERIVATIVE; FORMESTANE; ISOLICOFLAVONOL; LETROZOLE; NARINGENIN; QUERCETIN; ROTENONE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIANDROGEN;

ADVERSE OUTCOME; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PREVENTION; CATALYSIS; CEREBROVASCULAR DISEASE; COLON CANCER; CONFERENCE PAPER; DRUG MECHANISM; DRUG TOLERABILITY; ENDOMETRIUM CANCER; HORMONE RELEASE; HOT FLUSH; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; PHYTOCHEMISTRY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; AGARICALES; BREAST TUMOR; CHEMISTRY; ENZYMOLOGY; FEMALE; GRAPE; ISOLATION AND PURIFICATION; REVIEW;

AGARICALES; ANDROGEN ANTAGONISTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; VITIS;

EID: 33847796753     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1386.022     Document Type: Conference Paper

References (74)

1. ESTEBAN, J.M. et al. 1992. Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am. J. Pathol. 140: 337-343.
2. BULUN, S.E. et al. 1993. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J. Clin. Endocrinol. Metab. 77: 1622-1628.
3. HARADA, N. 1997. Aberrant expression of aromatase in breast cancer tissues. J. Steroid. Biochem. Mol. Biol. 61: 175-184.
4. JAMES, V.H. et al. 1987. Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 50: 269-279.
5. LU, Q. et al. 1996. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137: 3061-3068.
6. MILLER, W.R. & J. O'NEILL. 1987. The importance of local synthesis of estrogen within the breast. Steroids 50: 537-548.
7. SANTEN, R.J. et al. 1994. Stromal spindle cells contain aromatase in human breast tumors. J. Clin. Endocrinol. Metab. 79: 627-632.
8. SUN, X.Z., D. ZHOU & S. CHEN. 1997. Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells. J. Steroid Biochem. Mol. Biol. 63: 29-36.
9. VERMEULEN, A. et al. 1986. Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur. J. Cancer Clin. Oncol. 22: 515-525.
10. CASTAGNETTA, L.A. et al. 2003. Local estrogen formation by nontumoral, cirrhotic, and malignant human liver tissues and cells. Cancer Res. 63: 5041-5045.
11. KAO, Y.C. et al. 1999. Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women. Anticancer Res. 19: 2049-2056.
12. AGARWAL, V.R. et al. 1998. Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J. Clin. Endocrinol. Metab. 83: 1797-1800.
13. HARADA, N. et al. 1998. Localized aberrant expression of cytochrome P450 aromatase in primary and metastatic malignant tumors of human liver. J. Clin. Endocrinol. Metab. 83: 697-702.
14. WEINBERG, O.K. et al. 2005. Aromatase inhibitors in human lung cancer therapy. Cancer Res. 65: 11287-11291.
15. ZHOU, X.D., W.Q. CAI & H.W. CAO. 2002. Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer. Ai Zheng. 21: 259-262.
16. ENGLISH, M.A. et al. 1999. Loss of estrogen inactivation in colonic cancer. J. Clin. Endocrinol. Metab. 84: 2080-2085.
17. FIORELLI, G. et al. 1999. Estrogen synthesis in human colon cancer epithelial cells. J. Steroid Biochem. Mol. Biol. 71: 223-230.
18. CHENG, Y.S. et al. 2006. Aromatase expression in normal human oral keratinocytes and oral squamous cell carcinoma. Arch. Oral. Biol. 51: 612-620.
19. SANTEN, R.J. 1981. Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review. Breast Cancer Res. Treat. 1: 183-202.
20. BERETTA, K.R. et al. 1990. CGS 16949A, a newaromatase inhibitor in the treatment of breast cancer-a phase I study. Ann Oncol. 1: 421-426.
21. DOWSETT, M. et al. 1989. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 49: 1306-1312.
22. BRODIE, A.M. 1994. Aromatase inhibitors in the treatment of breast cancer. J. Steroid. Biochem. Mol. Biol. 49: 281-287.
23. COOMBES, R.C. et al. 1984. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 2: 1237-1239.
24. PLOURDE, P.V. et al. 1995. ARIMIDEX: a neworal, once-a-day aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 53: 175-179.
25. LIPTON, A. et al. 1995. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 75: 2132-2138.
26. EVANS, T.R. et al. 1992. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res. 52: 5933-5939.
27. BAUM, M. et al. 2002. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139.
28. SMITH, I.E. & M. DOWSETT. 2003. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348: 2431-2442.
29. COOMBES, R.C. et al. 2004. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausalwomen with primary breast cancer. N. Engl. J. Med. 350: 1081-1092.
30. GOSS, P.E. et al. 2003. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349: 1793-1802.
31. BRUEGGEMEIER, R.W., J.C. HACKETT & E.S. DIAZ-CRUZ. 2005. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 26: 331-345.
32. COVEY, D.F. & W.F. HOOD. 1981. Enzyme-generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene- 3,17-dione cause a time-dependent decrease in human placental aromatase activity. Endocrinology 108: 1597-1599.
33. FURTH, P.S. & C.H. ROBINSON. 1989. Tritium release from [19-3H]-19,19-difluoroandrost-4-ene-3,17-dione during inactivation of aromatase. Biochemistry 28: 1254-1259.
34. NUMAZAWA, M., K. MIDZUHASHI & M. NAGAOKA. 1994. Metabolic aspects of the 1 beta-proton and the 19-methyl group of androst-4-ene-3,6,17-trione during aromatization by placental microsomes and inactivation of aromatase. Biochem Pharmacol. 47: 717-726.
35. BRUEGGEMEIER, R.W. 1993. Steroidal inhibitors as chemical probes of the active sites of aromatase. J. Steroid Biochem. Mol. Biol. 44: 357-365.
36. GIUDICI, D. et al. 1988. 6-Methylenandrosta-1,4-diene-3, 17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem. 30: 391-394.
37. WANG, X. & S. CHEN. 2006. Aromatase destablizer: novel action of exemestane, an FDA approved aromatase inhibitor. Cancer Res. In press.
38. ZHOU, D.J., D. POMPON & S.A. CHEN. 1990. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res. 50: 6949-6954.
39. ZHOU, D.J., D. POMPON & S.A. CHEN. 1991. Structure-function studies of human aromatase by site-directed mutagenesis: kinetic properties of mutants Pro-308 - Phe, Tyr-361 - Phe, Tyr-361 - Leu, and Phe-406 - Arg. Proc. Natl. Acad. Sci. USA 88: 410-414.
40. ZHOU, D.J. et al. 1992. A site-directed mutagenesis study of human placental aromatase. J. Biol. Chem. 267: 762-768.
41. CHEN, S. & D. ZHOU. 1992. Functional domains of aromatase cytochrome P450 inferred from comparative analyses of amino acid sequences and substantiated by site-directed mutagenesis experiments. J. Biol. Chem. 267: 22587-22594.
42. KADOHAMA, N. et al. 1993. Catalytic efficiency of expressed aromatase following site-directed mutagenesis. Biochim. Biophys. Acta 1163: 195-200.
43. AMARNEH, B. et al. 1993. Functional domains of human aromatase cytochrome P450 characterized by linear alignment and site-directed mutagenesis. Mol. Endocrinol. 7: 1617-24.
44. CHEN, S. et al. 1993. Structure-function studies of human aromatase. J. Steroid. Biochem. Mol. Biol. 44: 347-356.
45. ZHOU, D. et al. 1994. Mutagenesis study at a postulated hydrophobic region near the active site of aromatase cytochrome P450. J. Biol. Chem. 269: 19501-19508.
46. GRAHAM-LORENCE, S. et al. 1995. A three-dimensional model of aromatase cytochrome P450. Protein Sci. 4: 1065-1080.
47. CHEN, S. et al. 2003. Structure-function studies of aromatase and its inhibitors: a progress report. J. Steroid. Biochem. Mol. Biol. 86: 231-237.
48. KAO, Y.C. et al. 1996. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res. 56: 3451-3460.
49. KAO, Y.C. et al. 2000. Catalytic differences between porcine blastocyst and placental aromatase isozymes. Eur. J. Biochem. 267: 6134-6139.
50. KAO, Y.C. et al. 2001. Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study. Eur. J. Biochem. 268: 243-251.
51. ZHAO, J. et al. 2001. Different catalytic properties and inhibitor responses of the goldfish brain and ovary aromatase isozymes. Gen. Comp. Endocrinol. 123: 180-191.
52. FAVIA, A.D. et al. 2006. Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins 62: 1074-1087.
53. HONG, Y. et al. 2006. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol. Endocrinol. In press.
54. MA, C.X. et al. 2005. Human aromatase: gene resequencing and functional genomics. Cancer Res. 65: 11071-11082.
55. ADLERCREUTZ, H. 1995. Phytoestrogens: epidemiology and a possible role in cancer protection. Environ. Health Perspect. 103(Suppl 7): 103-112.
56. GLADE, M.J. 1999. Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research, 1997. Nutrition 15: 523-526.
57. GRUBE, B.J. et al. 2001. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J. Nutr. 131: 3288-3293.
58. ENG, E.T. et al. 2003. Suppression of estrogen biosynthesis by procyanidin dimers in red wine and grape seeds. Cancer Res. 63: 8516-8522.
59. KIJIMA, I. et al. 2006. Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression. Cancer Res. 66: 5960-5967.
60. LEE, D. et al. 2001. Aromatase inhibitors from Broussonetia papyrifera. J. Nat. Prod. 64: 1286-1293.
61. FILLEUR, F. et al. 2001. Antiproliferative, anti-aromatase, anti-17beta-HSD and antioxidant activities of lignans isolated from Myristica argentea. Planta Med. 67: 700-704.
62. SANDERSON, J.T. et al. 2004. Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol. Sci. 82: 70-79.
63. BRUEGGEMEIER, R.W. et al. 2001. Effects of phytoestrogens and synthetic combinatorial libraries on aromatase, estrogen biosynthesis, and metabolism. Ann. N. Y. Acad. Sci. 948: 51-66.
64. KAO, Y.C. et al. 1998. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ. Health Perspect. 106: 85-92.
65. PELISSERO, C. et al. 1996. Effects of flavonoids on aromatase activity, an in vitro study. J. Steroid. Biochem. Mol. Biol. 57: 215-223.
66. CAMPBELL, D.R. & M.S. KURZER. 1993. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J. Steroid. Biochem. Mol. Biol. 46: 381-388.
67. CHEN, S., Y.C. KAO & C.A. LAUGHTON. 1997. Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase. J. Steroid. Biochem. Mol. Biol. 61: 107-115.
68. KIM, Y.W., J.C. HACKETT & R.W. BRUEGGEMEIER. 2004. Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J. Med. Chem. 47: 4032-4040.
69. GOBBI, S. et al. 2006. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J. Med. Chem. 49: 4777-4780.
70. RECANATINI, M. et al. 2001. A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20- lyase. J. Med. Chem. 44: 672-680.
71. CHEN, S. et al. 2004. Biochemical and biological characterization of a novel antiaromatase coumarin derivative. J. Biol. Chem. 279: 48071-48078.
72. BALUNAS, M.J. et al. 2006. Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay. J. Nat. Prod. 69: 700-703.
73. ENG, E.T. et al. 2002. Anti-aromatase chemicals in red wine. Ann. N. Y. Acad. Sci. 963: 239-246.
74. ENG, E.T. et al. 2001. Suppression of aromatase (estrogen synthetase) by red wine phytochemicals. Breast Cancer Res. Treat. 67: 133-146.